Trends in Cardiovascular Medicine
Volume 15, Issue 4 , Pages 158-161 , May 2005

The Role of High-Density Lipoprotein in Inflammation

  • Mohamad Navab

      Affiliations

    • Corresponding Author InformationAddress correspondence to: Mohamad Navab, PhD, Division of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California in Los Angeles, Room 47-123 CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095-1679, USA. Tel.: (+1) 310-206-2678; fax: (+1) 310-206-9133
    • ,
  • G.M. Anantharamaiah
    • ,
  • Alan M. Fogelman

References 

  1. Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751–2756
  2. Binder CJ, Chang M-K, Shaw PX, et al. Innate and acquired immunity in atherogenesis. Nat Med. 2002;8:1218–1226
  3. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport. Proc Natl Acad Sci USA. 2004;101:13032–13037
  4. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–1397
  5. Eisenberg S. High density lipoprotein metabolism. J Lipid Res. 1984;25:1017–1058
  6. Fogelman AM. When good cholesterol goes bad. Nat Med. 2004;10:902–903
  7. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448–454
  8. Hamm H, Pfalzer B, Fabel H. Lipoprotein analysis in chyliform pleural effusion. Respiration. 1991;58:294–300
  9. Hazen SM. Myeloperoxidase and plaque vulnerability. Arterioscler Thromb Vasc Biol. 2004;24:1143–1146
  10. Heinecke JW. Oxidative stress: new approaches to diagnosis and prognosis in atherosclerosis. Am J Cardiol. 2003;91:12A–16A
  11. Khovidhunkit W, Duchateau PN, Medzihradszky KF, et al. Apolipoproteins A-IV and A-V are acute phase proteins in mouse HDL. Atherosclerosis. 2004;176:37–44
  12. Khovidhunkit W, Kin M-S, Memon RA, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–1196
  13. Mackness B, Hunt R, Durrington PN, et al. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233–1238
  14. Navab M, Hama SY, Cooke CJ, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res. 2000;41:1481–1494
  15. Navab M, Hama SY, Anantharamaiah GM, et al. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res. 2000;41:1495–1508
  16. Navab M, Van Lenten BJ, Reddy ST, Fogelman AM. High-density lipoprotein and the dynamics of atherosclerotic lesions. Circulation. 2001;104:2386–2387
  17. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an apoA-I mimetic peptide synthesized from d-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 2002;105:290–292
  18. Navab M, Anantharamaiah GM, Reddy ST, et al. Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 2004;109:r120–r125
  19. Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res. 2004;45:993–1007
  20. Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2005;25:1–7[electronic publication ahead of print]
  21. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005;25:1–7[electronic publication ahead of print]
  22. Pennathur S, Berg C, Shao B, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem. 2004;279:42977–42983
  23. Ridker PM. On evolutionary biology, inflammation, infection, and the causes of atherosclerosis. Circulation. 2002;105:2–4
  24. Shishehbor MH, Aviles RJ, Brennan M-L, et al. Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA. 2003;289:1675–1680
  25. Shishehbor MH, Brennan M-L, Aviles RJ, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways. Circulation. 2003;108:426–441
  26. Tsimikas S, Lau HK, Han K-R, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a). Short and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 2004;109:3164–3170
  27. Van Lenten BJ, Hama S, deBeer FC, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758–2767
  28. Van Lenten BJ, Wagner AC, Anantharamaiah GM, et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation. 2002;106:1127–1132
  29. Van Lenten BJ, Wagner AC, Navab M, et al. D-4F, an apolipoprotein A-I mimetic peptide, inhibits the inflammatory response induced by influenza A infection of human type II pneumocytes. Circulation. 2004;110:3252–3258
  30. Zhang Y, Zanotti I, Reilly MP, et al. Overexpression of apolipoprotein A-I promotes reverse transport of cholesterol from macrophages to feces in vivo. Circulation. 2003;108:661–663
  31. Zheng L, Nukuna B, Brennan M-L, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114:529–541
  32. Zheng L, Settle M, Brubaker G, et al. Localization of nitration and chlorination sites on apolipoprotein A-I catalyzed by myeloperoxidase in human atheroma and associated oxidative impairment in ABCA1-dependent cholesterol efflux from macrophages. J Biol Chem. 2005;280:38–47

 MN, GMA, and AMF are principals in Bruin Pharma.

PII: S1050-1738(05)00062-9

doi: 10.1016/j.tcm.2005.05.008

Trends in Cardiovascular Medicine
Volume 15, Issue 4 , Pages 158-161 , May 2005

Article Tools

* Image Usage & Resolution